Johnson & Johnson’s global sales of contact lenses fell by 4.4 percent year-on-year in the fourth quarter to $796 million. At constant currency rates, the decline widened to 5.3 percent as sales continued to be impacted by the Covid-19 pandemic. Lower levels of stocking in the U.S. also weighted on sales in J&J’s domestic market, which went down by 7.4 percent to $289, while the decline in international sales was limited at 4.1 percent on a currency neutral basis.

For the full year, the group’s sales of contact lenses fell by 11.5 percent to $2,994 million on a currency neutral basis. In the U.S., revenues went down by 7.0 percent to $1,213 million, while international sales were more severely hit, sliding by 14.4 percent in constant currencies to $1,781 million. However, the company commented that the negative impact of the pandemic had been partially offset by the continued success of the Acuvue Oasys product range, without giving specific numbers.

As regards J&J’s vision care division, which also includes other eye health products and surgical solutions, sales went down to $3,919 million for the year, a 15.1 percent drop in constant currencies as compared to 2019. At group level and in reported terms, J&J’s top line inched up by 0.6 percent to $82,584 million while EDITDA declined by 4.8 percent to $16,497 million.